GlassScriptPhysician profile
Katherine A Hoffman
NPI 1992372361
$6,954.07
in general payments reported to CMS, 2019-2025
18 companies · $1,100 in 2025
The $1,100 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $442 · 2022: $1,298 · 2023: $2,384 · 2024: $1,730 · 2025: $1,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,209 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,208.94 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $1,086.71 | 2021-2025 | Abilify Maintena, Rexulti |
| Janssen Pharmaceuticals, INC | $1,070.42 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $775.16 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $772.95 | 2021-2025 | Caplyta |
| Alkermes, INC. | $762.44 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $650.91 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $444.27 | 2022-2024 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $287.57 | 2022-2025 | Austedo Xr, Austedo, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $240.91 | 2021-2025 | Trintellix |
| Corium, LLC | $225.02 | 2022-2023 | Azstarys |
| Axsome Therapeutics, INC. | $207.39 | 2022-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $162.95 | 2021-2025 | Ingrezza |
| Noven Therapeutics, LLC | $122.45 | 2023-2025 | Xelstrym |
| Sunovion Pharmaceuticals INC. | $51.01 | 2022 | |
| Vanda Pharmaceuticals INC. | $35.72 | 2021-2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $26.20 | 2025 | Loreev Xr |
| Neos Therapeutics, LP | $17.00 | 2025 | Adzenys Xr-Odt |
| Idorsia Pharmaceuticals US INC | $14.99 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.